Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ovid TherapeuticsOVID +2.32%48 3-Year EPS without NRI Growth Rate is 33.20% as of Jun. 2026, which is 71% above its 10-year median of 19.45. GuruFocus rates OVID with a GF Score™ of 48/100 and a GF Value™ of $6.45 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,160 Biotechnology companies, Ovid Therapeutics ranks better than 70.34% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 33.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 11 years, the highest 3-Year average EPS without NRI Growth Rate of Ovid Therapeutics was 33.20% per year. The lowest was -46.50% per year. And the median was 19.45% per year.
Ovid Therapeutics (NAS:OVID) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Ovid Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
OVID vs SGMT, CABA, QTTB: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Ovid Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovid Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Ovid Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Ovid Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 33.20% mean?
Ovid Therapeutics (OVID) has a 3-Year EPS without NRI Growth Rate of 33.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ovid Therapeutics and its competitors. This is 71% above median its historical median of 19.45. According to the industry distribution chart, Ovid Therapeutics ranks #344 out of 1160 companies in the Biotechnology industry, placing it in the top 29.7%.
Is Ovid Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Ovid Therapeutics' current 3-Year EPS without NRI Growth Rate of 33.20% is 71% above median its 10-year median of 19.45. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Ovid Therapeutics' value of 33.20% is 104.9% above this industry median. Based on the distribution chart, Ovid Therapeutics ranks #344 out of 1160 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ovid Therapeutics has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ovid Therapeutics' 3-Year EPS without NRI Growth Rate compare to SGMT and CABA?
According to the Biotechnology industry distribution chart, Ovid Therapeutics ranks #344 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This puts Ovid Therapeutics in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Ovid Therapeutics' value of 33.20% is 104.9% above this benchmark. While the company's 10-year median is 19.45 vs. the industry median of 16.20, Ovid Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ovid Therapeutics's current 3-Year EPS without NRI Growth Rate of 33.20% is 104.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ovid Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ovid Therapeutics's current 3-Year EPS without NRI Growth Rate is 33.20%, which is 71% above median its own 10-year median of 19.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovid Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ovid Therapeutics (OVID) is currently considered Possible Value Trap. The stock's GF Value™ is $6.45, compared to a current price of $2.87 — trading 55.6% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 33.20%, which is 71% above median its 10-year median of 19.45 and 104.9% above the Biotechnology industry median of 16.20. Ovid Therapeutics' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Ovid Therapeutics (OVID), the current 3-Year EPS without NRI Growth Rate is 33.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ovid Therapeutics (OVID) Overvalued in 2026?
Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be undervalued.
The current stock price of $2.87 is trading 55.6% below its estimated GF Value™ of $6.45.
GuruFocus considers Ovid Therapeutics to be Possible Value Trap.
Key valuation signals for OVID:
3-Year EPS without NRI Growth Rate: 33.20% (71% above median its 10-year median of 19.45)
GF Value™: $6.45 vs. price of $2.87 (55.6% below fair value)
Industry Position: 104.9% above the Biotechnology median (#344 of 1160)
No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
48GF Score
Get the complete analysis for OVID
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OVID has been successfully added to your 
